Get the Stockscreener App
0.4338
3.14%
-0.0179
Passage Bio Inc stock is traded at $0.4338, with a volume of 188.29K.
It is down -3.14% in the last 24 hours and up +34.20% over the past month.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
See More
Previous Close:
$0.4517
Open:
$0.443
24h Volume:
188.29K
Relative Volume:
0.81
Market Cap:
$26.73M
Revenue:
-
Net Income/Loss:
$-68.80M
P/E Ratio:
-0.3708
EPS:
-1.17
Net Cash Flow:
$-59.06M
1W Performance:
+18.24%
1M Performance:
+34.20%
6M Performance:
-61.28%
1Y Performance:
-61.96%
1-Day Range:
$0.4065
$0.45
1-Week Range:
$0.3362
$0.47
52-Week Range:
$0.257
$1.33
Passage Bio Inc Stock (PASG) Company Profile
Name
Passage Bio Inc
Sector
Industry
Phone
(267) 866-0312
Address
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
0.4301 | 21.68M | 0 | -68.80M | -59.06M | -1.17 |
|
ONC
Beone Medicines Ltd Adr
|
245.77 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.41 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.32 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
80.93 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.40 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Sep-03-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-08-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-19-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-01-21 | Initiated | Raymond James | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Mar-04-21 | Upgrade | Goldman | Neutral → Buy |
| Feb-04-21 | Initiated | Guggenheim | Buy |
| Jan-25-21 | Initiated | Wedbush | Outperform |
| Jan-04-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Aug-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-25-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-25-20 | Initiated | Chardan Capital Markets | Buy |
| Mar-24-20 | Initiated | Cowen | Outperform |
| Mar-24-20 | Initiated | Goldman | Buy |
| Mar-24-20 | Initiated | JP Morgan | Overweight |
View All
Passage Bio Inc Stock (PASG) Latest News
Layoff Tracker: Boundless Laying Off 33% of Staff - BioSpace
VintaBio Showcases Breakthrough Gene Therapy Manufacturing Platform - MyChesCo
Latus Bio Announces Breakthrough in Gene Therapy with AAV-Ep+ Capsid - MyChesCo
Metachromatic Leukodystrophy Pipeline 2025: Groundbreaking - openPR.com
GM1 Gangliosidosis Market: Epidemiology, Therapies, - openPR.com
Guggenheim Adjusts Price Target for Passage Bio (PASG) | PASG St - GuruFocus
Guggenheim Adjusts Price Target for Passage Bio (PASG) | PASG Stock News - GuruFocus
Cabaletta Bio Updates Progress on RESET-Myositis Trial and Regulatory Milestones - MyChesCo
Passage Bio Reports Q1 2025 Financial Results and Highlights Progress in Gene Therapy Development - MSN
Wedbush Issues Pessimistic Estimate for Passage Bio Earnings - Defense World
Gm1 Gangliosidosis Treatment Market in 2025 Detailed Study - openPR.com
Dimensional Fund Advisors LP Has $1.14 Million Stock Holdings in Traeger, Inc. (NYSE:COOK) - Defense World
TransAct Technologies Incorporated (NASDAQ:TACT) Shares Acquired by Dimensional Fund Advisors LP - Defense World
Passage Bio, Inc. (NASDAQ:PASG) Shares Acquired by Tower Research Capital LLC TRC - Defense World
Braskem Marks 15 Years of I’m green Bio-Based Portfolio with Expanded Production - MyChesCo
Passage Bio Reports Q1 2025 Financial Results - TipRanks
Wedbush Adjusts Price Target on Passage Bio to $3 From $4, Maintains Outperform Rating - marketscreener.com
Passage Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Passage Bio Q1 Income From Operations USD -16.459 Million - marketscreener.com
Passage Bio (PASG) Advances Phase 1/2 Trial for PBFT02, Eyes Fut - GuruFocus
Passage BIO, Inc. SEC 10-Q Report - TradingView
Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights - GlobeNewswire
Passage Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025 - The Manila Times
Passage Bio (PASG) Expected to Announce Earnings on Tuesday - Defense World
2025 Q1 Job Market Report: Quarterly Job Postings Live Declined as Applications Spiked - BioSpace
Annovis Bio Appoints Hui Liu as Director of Biostatistics - MyChesCo
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc: A Strategic Portfolio Adjustment - GuruFocus
Fierce Biotech Layoff Tracker 2025: Entrada cuts 20% of workforce; Ono lays off 83 staffers - Fierce Biotech
Orbimed advisors sells Passage Bio stock for $49,704 - Investing.com Australia
Orbimed advisors sells Passage Bio stock for $49,704 By Investing.com - Investing.com Canada
Passage Bio (NASDAQ:PASG) vs. Agenus (NASDAQ:AGEN) Critical Contrast - The AM Reporter
Analyzing Agenus (NASDAQ:AGEN) & Passage Bio (NASDAQ:PASG) - Defense World
PASG stock touches 52-week low at $0.3 amid market challenges - Investing.com Australia
Frontotemporal Dementia Pipeline 2025: Key Companies, MOA, - openPR.com
GM1 Gangliosidosis Treatment Market: Advances & Emerging - openPR.com
Cabaletta Bio Reports Strong Clinical Progress and Q4 2024 Financial Results - MyChesCo
Passage Bio stock plunges to 52-week low of $0.35 By Investing.com - Investing.com South Africa
Passage Bio stock plunges to 52-week low of $0.35 - Investing.com
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Krabbe Disease Treatment Market is to grow at a 7.22 % CAGR, with the United States leading the market through 2032 - StreetInsider.com
Strategic Partnership To Advance Gene Therapies For Rare Diseases: Key Trend in The GM1 Gangliosidosis Glob... - WhaTech
Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MyChesCo
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Passage Bio Inc Stock (PASG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Passage Bio Inc Stock (PASG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 10% Owner |
Apr 22 '25 |
Sale |
0.34 |
78,049 |
26,537 |
6,807,523 |
| ORBIMED ADVISORS LLC | 10% Owner |
Apr 24 '25 |
Sale |
0.32 |
68,195 |
21,822 |
6,650,000 |
| ORBIMED ADVISORS LLC | 10% Owner |
Apr 17 '25 |
Sale |
0.33 |
77,090 |
25,440 |
6,885,572 |
| ORBIMED ADVISORS LLC | 10% Owner |
Apr 16 '25 |
Sale |
0.33 |
61,638 |
20,341 |
6,962,662 |
| ORBIMED ADVISORS LLC | 10% Owner |
Apr 15 '25 |
Sale |
0.38 |
10,326 |
3,924 |
7,024,300 |
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):